Contrast Media Market to Perceive Momentous Accruals with a hefty CAGR By 2025

 Contrast Media Market Insight

The contrast media/ contrast agents market is making significant strides over recent years, mainly due to the rapidly developing medical imaging technologies. Besides, strong headways in terms of product developments and their approvals drive the growth of the market. The healthcare sector is burgeoning and medical imaging technology & techniques are advancing profusely. These advancements have improved the utilization of the existing contrast media while presenting innovative agents. This, in turn, escalates the market to furthered height. 

According to Market Research Future (MRFR), the Global Contrast Media Market size is estimated to increase exponentially by 2025, registering approximately 3.5% CAGR during the review period (2019 – 2025). Increasing uses of contrast media in medical imaging to enhance the visibility of blood vessels & GI tract support the growth of the market. Moreover, rising numbers of contrast media approvals act as a key tailwind pushing the market forward. Simultaneously, the rising expectations of radiologists augment market demand.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1284  

Additionally, the rising prevalence of various chronic diseases such as GIT, cancer, cardiac conditions, and an increase in the number of public as well as private diagnostic centers are fostering market growth. Also, the demand for improved diagnostic imaging services and various diagnostic imaging modalities are creating substantial market demand. On the flip side, the risk of side / adverse effects of the contrast media is impeding the market growth. However, technological innovations would support the contrast media market growth, improving media functionalities. 

Contrast Media Market Major Players

Players active in the global contrast media market include NanoScan Imaging (US), Bayer Healthcare Pharmaceuticals (Germany), Daiichi (Japan), Medrad Inc. (US), Guerbet Group (France), Subhra Pharma Private Limited (India), GE Healthcare (US), nanoPET Pharma GmbH (Germany), Covidien (Ireland), AMAG Pharmaceuticals (US), CMC Contrast AB (Sweden), Targeson (US), Mallinckrodt Pharmaceuticals (UK), Lantheus Medical Imaging (US), and Bracco Diagnostic Inc. (Italy), among others. 

Global Contrast Media Market – Segments

The analysis has been segmented into six main dynamics.

• By Type: Iodinated Contrast Media and Gadolinium-Based Contrast Media, and others.

• By Form:Tablet, Powder, Liquid, and Paste.

• By Procedure: Computed Tomography, X-ray, Ultrasound, Magnetic Resonance Imaging, and other procedures.

• By Application: Oncology, Cardiovascular Disorders, Nephrological Disorders, and others.

• By Route of Administration: Injectable, Oral, and Rectal.

• By Regions:Asia Pacific, North America, Europe, and the Rest-of-the-World. 

Global Contrast Media Market – Geographical Analysis

North America dominates the global contrast media market. The largest market share majorly attributes to the advancements in the medical & imaging technologies. Furthermore, the increasing prevalence of chronic diseases and massive uptake of advanced technologies for the diagnosis of myriad diseases & disorders drive the regional market growth. The presence of notable players and their increasing emphasis on delivering cost-competitive product range foster the growth of the contrast media market in the region.

Europe accounts for the second-largest market share in the global contrast media market. Increasing healthcare expenditures and the adoption of advanced technologies boost regional market growth.  Also, the presence of many global players in the region is another key driving the growth of the regional market.  Additionally, the growth of the medical supplies market in the region fosters the European contrast media market. 

The Asia Pacific region is becoming a profitable market for Contrast Medias, globally. Factors such as the rapidly increasing healthcare sectors and developing economy in the region are pushing the growth of the market. Besides, profusely developing APAC countries such as India, Japan, and China, contribute to the regional market growth, significantly. Also, the rising population and spreading awareness for the functionalities of contrast media influence the market growth in the APAC region.

Global Contrast Media Market – Competitive Analysis

The market appears highly competitive and diversified with the presence of several well-established players. To gain a larger competitive advantage in the market, players adopt strategies such as mergers & acquisitions, expansion, collaboration, and product & technology launch. They make substantial R&D investments in developing new products and manufacturing technology. 

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/contrast-media-market-1284 

Global Skin Tightening Market Expected to Grow with a healthy CAGR

 Market Highlights

The Global Skin Tightening Market is forecasted to be valued at USD 6,340.99 Million by 2025 with the CAGR of 6.2% during the forecast period of 2019–2025.

According to International Society of Aesthetic Plastic Surgery (ISAPS), in 2016, estimated the total procedure for skin tightening performed worldwide are 511,481 out of which Japan held the highest number of procedures followed by the US.  The factors that propel the growth of the market are growing geriatric population, increasing advancement in medical technology and the emerging medical aesthetic market.

However, the radiation emitted from skin tightening equipment involve high health-related risk and the stringent government regulations for aesthetic in healthcare is hampering the growth of the skin tightening market.  

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8245 

In the current scenario, several players are dominating the global skin tightening market. The market leaders in skin tightening treatment are involved in merger and acquisition, product development and innovation to increase the foothold in the skin tightening market. For instance, in January 2017, Lynton Lasers launched a stand-alone platform, LUMINA laser & IPL platform, which can perform 24 different aesthetic concern including skin tightening.

Regional Analysis

The global skin tightening market, by region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The skin tightening market in the Americas is estimated to hold the largest market share. In 2016, according to ISAPS, the total number of skin tightening procedure performed are 75,834. The European skin tightening market has been sub-divided into Western Europe and Eastern Europe. Germany is expected to hold the largest market share in the European region followed by Italy.  

The skin tightening market in Asia-Pacific region is expected to be the fastest-growing market, due to increasing research and development funding by the developing countries like China and India for the development of the healthcare sector. The skin tightening market in the Middle East & Africa region has less economic developments and extremely low-income, therefore anticipated to have the least market share but is expected to grow with better opportunities in the coming years.

Segmental Analysis

The global skin tightening market has been segmented based on type, portability, application, end user, and region.

The market, based on type, has been divided into radiofrequency skin tightening, laser skin tightening, ultrasound skin tightening, and others. The radiofrequency skin tightening segment is anticipated to hold the largest share in the market due to the wider preferability and long-lasting results.

The market, based on portability, has been segregated into portable and stand-alone. The stand-alone market is expected to hold the largest share in the market, owing to its increasing application in the medical devices industry.

The market, by application, has been categorized as reduce wrinkles, face lifting, anti-aging, and others. The anti-aging segment is expected to lead the market owing to the increasing focus and concern toward having a youthful appearance.

The market, by end user, has been classified as hospitals & clinics, specialty center, and others. The specialty center segment is anticipated to hold a major share in the market due to the professional skin tightening treatments provided in these establishments.

Key Players

Some of the key players in the global skin tightening market are  ALLERGAN (US), Solta Medical (US), Venus Concept (Canada), SmarterSkin Dermatology (US), INMODE (US), Fotona d.o.o. (Slovenia), BTL (US), Lynton Lasers (UK), EINS MED Co., Ltd (South Korea), ENDYMED MEDICAL (US), and Alma Lasers (Israel). 

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/skin-tightening-market-8245 

Durable Medical Equipment Market is Expected to Exhibit a Strong CAGR during forecast period upto 2025

 Market Scenario

The global durable medical equipment market is expected to grow significantly over the forecast period. It is anticipated that the market held a market value of USD 1,08,553.8 million in 2018 and is projected to grow at 6% CAGR over the forecast period.

Medical equipment can be classified into two types disposable medical equipment and durable medical equipment. Durable medical equipment is reusable and can be used for the long run. The medical devices such as insulin pump, ostomy bags, and hospital furniture are considered under durable medical equipment and are used for years.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2676  

The growing geriatric patient population, rising demand for medical equipment, and growing technological innovation in the medical devices industry are boosting the market growth. Additionally, the medical coverage provided for medical equipment drives market growth. The different private insurance companies provide insurance coverage for medical equipment drives market growth.

However, the high maintenance and equipment cost, stringent government regulation, and lack of skilled professionals to handle this equipment can hamper the market growth over the forecast period. 

Segmentation

The global durable medical equipment market has been segmented into device type and end user.

The global market, based on device type, has been segmented into personal mobility devices, medical furniture, monitoring and therapeutic devices, and bathroom safety devices. The personal mobility devices segment has been sub-segmented into wheelchair, crutch and cane, walker and rollators, and other personal mobility devices. The medical furniture segment is sub-segmented into medical bed and mattress, lift chairs, stretchers, and others. The monitoring and therapeutic devices segment is sub-segmented into blood glucose monitor, oxygen equipment, vital sign monitor, continuous passive motion (CPM), infusion pump, traction equipment, ostomy bags and accessories, cardiology devices, orthopedic braces and support, diabetic supplies, and others. The bathroom safety devices segment has been sub-segmented into commode, toilet, and others.

The global market, by end user, has been segmented into hospital/clinic, ambulatory surgical center, research centers, home healthcare, and others.

The durable medical equipment market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The durable medical equipment market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The increasing patient population, presence of a large number of medical device companies, and rising demand for innovative medical equipment drive the market growth in this region.

The European durable medical equipment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The Asia-Pacific durable medical equipment market has been segmented into Japan, China, India, Latin Korea, Australia, and the rest of Asia-Pacific.

The durable medical equipment market in the Middle East & Africa has been segmented into the Middle East and Africa. There is an increase in the market growth in this region due to the increasing development in healthcare infrastructure and growing economy in countries such as Kuwait, Iran, Israel, and Iraq.  

Key Players

Compass Health Brand (US), GE Healthcare (US), Getinge AB (US), GF Health Products Inc. (US), Invacare Corporation (US), Medtronic Inc. (Ireland), Sunrise Medical (UK), Koninklijke Philips NV (UK), Medline Industries Inc. (US), Masimo (US), ArjoHuntleigh (UK), Hill-Rom (US), Stryker (US) and Medical Device Depot, Inc. (US) are some of the key players in the global durable medical equipment market. 

Regional Market Summary

Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global durable medical equipment market owing to a well-developed healthcare sector, the presence of a large number of medical device companies in this region boosts the market growth. Additionally, the presence of a large number of patient population suffering from chronic disorders and the rising demand for technologically advanced products is the key factor attributing to the growth of this region.  

Europe is expected to hold the second-largest position in the global durable medical equipment market. The increasing technological advancement in the healthcare industry, growing mergers & acquisition, and presence of a large number of healthcare organizations drives the market growth in this region. For instance, Alabama Durable Medical Equipment Association (ADMEA) is a Europe-based non-profit organization involved in providing home medical equipment in the region. Thus, such organizations drive market growth during the forecasted period.

Asia-Pacific is expected to be fastest-growing region owing to the huge patient pool suffering from chronic diseases such as diabetes, cancer, arthritis, asthma, and many more diseases. Additionally, the increasing geriatric population drives the growth of this market. According to a fact sheet published by the World Health Organization in February 2018, it was reported that in 2015, 12% of the world's population was over 60 years and estimated that it will increase to 22% by 2050. The growing geriatric population across the world is expected to increase the burden of the patient population and ultimately drives the demand for medical equipment.

The Middle East & Africa holds the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to its well-developed healthcare sector and growing government initiatives for the development of the healthcare sector.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/durable-medical-equipment-market-2676 

Molecular Diagnostics Market is Expected to Exhibit a Strong CAGR during forecast period upto 2025

 Market Highlights

The Global Molecular Diagnostics Market is expected to register a CAGR of 8.57% during the forecast period, with a market value of USD 16,319.09 Million by 2025.

Molecular diagnostics is a collection of techniques used to analyze biological markers in genome and proteome. It helps to diagnose and monitor the diseases and decide which therapy should be administered to the patient based on the diagnosis. However, the rising prevalence of the infectious disease, increasing awareness regarding molecular diagnostic technique, and advancement in molecular diagnostics are the factors responsible for market growth during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1171  

Rising prevalence of infectious diseases, advancements in molecular diagnostic techniques, and increasing prevalence of different types of cancer are likely to contribute to the growth of the market during the assessment period. For instance, as per a survey carried out by the World Health Organisation (WHO), around 9.6 million deaths caused by cancer were recorded in 2018 globally. However, stringent regulatory policies are likely to restrain the market growth during the forecast period.

Segment Analysis

The global molecular diagnostics market has been segmented into product, technique, application, and end user. By product, the market has been segregated into reagents & kits, instruments, and services & software. On the basis of technique, the market has been divided into polymerase chain reaction (PCR), isothermal amplification, hybridization, sequencing, microarray, and others. Based on application, the market has been bifurcated into infectious diseases, oncology, genetic tests, and others. By end user, the market has been categorized as hospitals & clinics, diagnostic laboratories, and others. The hospitals & clinics segment accounted for a market value of USD 4.078.09 million in 2018.

Market Players

Market Research Future (MRFR) recognizes the following companies as key players in the global Molecular Diagnostics market that include F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), QIAGEN (Europe), Becton, Dickinson and Company (US), Abbott Laboratories (US), Cepheid (US), Siemens (Germany), CLONIT SRL (Italy), Thermo Fisher Scientific(US), Agilent Technologies(California), EKF Diagnostics (UK), Novartis (Switzerland), and Illumina (US).

Regional Analysis

The global molecular diagnostics market, based on region, has been classified as the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is estimated to dominate the global molecular diagnostics market during the forecast period. This is attributed to the increasing geriatric population, and the availability of advanced healthcare facilities in the region play a vital role in the growth of the regional market. The Europe market for molecular diagnostics is expected to be the second-largest during the forecast period. The availability of funds for research & development and rising support from the government toward the life science sector is expected to boost the growth of the market in this region.

Additionally, the companies operating in the market are mainly focusing on mergers & acquisition, which is expected to support market growth. Asia-Pacific is estimated to be the fastest-growing market due to developing economies such as China, India, and South Korea emerging as major destinations for the outsourcing of clinical trials, drug manufacturing, and pathology testing. In addition to this, improving healthcare infrastructure has increased the number of research activities in the region. Moreover, in Asia-Pacific, China accounted for a market share of 21.4% in 2018. Furthermore, the market in the Middle East & Africa is expected to witness steady growth during the review period due to the lack of awareness regarding healthcare facilities.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/molecular-diagnostics-market-1171 

Theranostics Market is Expected to Exhibit a Strong CAGR during forecast period upto 2025

 Market Highlights

The global theranostics market size accounted for USD 7,968.4 million in 2018 and is projected to grow at a CAGR of 11.4% over the forecast period. Theranostics is a new field of medicine which combines therapeutics, nanoscience, and diagnostics based on specific targeted diagnostic tests. Theranostics is also called as theragnostics or companion diagnostics (CDx), or pharmacodiagnostics or personalized medical care, or personalized therapy, or personalized medicine technology. Theranostics is a proposed diagnostic methodology for personalizing therapeutic intervention and the integration of imaging and therapy in a single system, enabling simultaneous therapy and follow-up of the treatment. Some of the market growth factors are increasing development of novel companion diagnostic tests, emerging use of theranostics, increasing partnerships and collaborations by major market players to develop innovative companion diagnostics, and rising burden of chronic diseases. In contrast, lack of proper defined regulations for theranostics tests and inadequate reimbursement facilities in most of the countries are anticipated to impede the market growth during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8057 

Molecular theranostics is a major field which includes small biochemical moieties and biomacromolecules. Theranostics is important for personalized as well as precision medicine that provides therapeutic outcome so that a physician can make a decision pertaining to the course of treatment for the patient.

Segmentation

The global theranostics market has been segmented into the therapeutic area, technology, end user, and region.

By therapeutic area, the market has been segmented into oncology, cardiovascular diseases, neurological disorders, immunological disorders, and others. The oncology segment is further categorized into breast cancer, colorectal cancer, lung cancer, cervical cancer, and others.

On the basis of technology, the market has been divided into polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), sequencing, and others. The sequencing segment is likely to register comparatively higher CAGR over the forecast period due to the increasing number of proof-of-concept case studies and research related to sequencing, particularly next-generation sequencing (NGS) technology.

Based on end user, the market has been classified into hospitals and clinics, diagnostic laboratories, and others.

Key Players

Few of the prominent players in the global theranostics market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Focus Diagnostics, Abbott Laboratories, Illumina, Inc., Agilent Technologies, Inc., QIAGEN, Myriad Genetics, Inc., Foundation Medicine, Inc., and AmeriPath, Inc.

Regional Analysis

The global theranostics market has been categorized on the basis of region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. On a regional basis, the Americas would command the market throughout the forecast period attributed to the domicile of major market participants, increasing research and development activities, and growing adoption of theranostics in the US and Canada. For instance, in June 2018, Genome Canada launched a national initiative for clinical implementation of precision health that would ultimately impact the market growth in the near future.

Europe would follow Americas in terms of value over the forecast period due to flourishing pharmaceutical and medical device companies, increasing partnerships and collaborations between life science companies and medical diagnostics companies, and growing personalized medicine sector. Personalized medicine (PM) is an emerging approach to prevention, diagnosis, treatment, and care which is assisting in addressing the challenge of the aging of the population, rising prevalence of chronic diseases, and increasing healthcare costs.

The market in Asia-Pacific would register the fastest market growth over next seven years owing to booming medical tourism, swiftly developing healthcare infrastructure, and growing awareness in the developing countries, namely, India, China, Singapore, and Australia.

The Middle East & Africa has the least share of the global theranostics market. In addition, the major market share of the region would be held by the Middle Eastern region due to developing healthcare system and medical infrastructure in the Arab countries.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/theranostics-market-8057 

Active Pharmaceutical Ingredients Market Scope And Challenges 2020-2023 by Players, Types and Applications

 Market Highlights

The active pharmaceutical ingredient (API) market globally is expected to expand with a CAGR of 4.93 percent during the forecast period while earning revenues past the USD 215 billion mark by the year 2023. The outlook for growth in the economy is likely to perceive a sweeping rise in the API industry owing to the growing occurrence of chronic disorders such as diabetes, cardiovascular diseases, obesity and other infectious diseases which will lead to the launch of numerous innovative drugs. The rising cases of chronic diseases are also one of the foremost reasons for hospitalization with a huge number of patients with these conditions who may need re-admission in hospitals owing to an infection that can cause other chronic diseases. The expiration of patents of branded drugs has created a serious impression on drug manufacturers, as the companies can incur tremendous losses after expiration. Hence, the producers favor generic drugs over the branded ones. The generics are also expected to be the most rapidly growing type due to patent expirations of many blockbuster drugs.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1385 

Active Pharmaceutical Ingredients or API, in short, are growing in an increscent manner due to the unmatched effects of active chemicals in the drugs and the portions that work on treating the condition. The bridging of foreign manufacturers and local distributors has led to extensive progress in the market over the past few years. The launch of innovative and improved APIs in the market will boost the market’s progress to a great extent in the forthcoming period. Moreover, the constantly growing demand for biotech API has stimulated the firms to present better and new products to address the unmet requirements of the market.

The active pharmaceutical ingredient (API) market globally is expected to expand with a CAGR of 4.93 percent during the forecast period while earning revenues past the USD 215 billion mark by the year 2023. The outlook for growth in the economy is likely to perceive a sweeping rise in the API industry owing to the growing occurrence of chronic disorders such as diabetes, cardiovascular diseases, obesity and other infectious diseases which will lead to the launch of numerous innovative drugs. The rising cases of chronic diseases are also one of the foremost reasons for hospitalization with a huge number of patients with these conditions who may need re-admission in hospitals owing to an infection that can cause other chronic diseases. The expiration of patents of branded drugs has created a serious impression on drug manufacturers, as the companies can incur tremendous losses after expiration. Hence, the producers favor generic drugs over the branded ones. The generics are also expected to be the most rapidly growing type due to patent expirations of many blockbuster drugs.

However, the rapidly increasing scope for high-potency active pharmaceutical ingredients over the last decade has shifted the focus to the new biologics gold rush of recombinant proteins and monoclonal antibodies. As a result of this, the chemical API market for western contract manufacturers, on the whole, has undergone a sharp decline till 2015. Many custom manufacturing organizations (CMOs) have shifted their emphasis to rescheduling plants or manufacturing of higher-value biologics.

Segmental Analysis

The segmental analysis of the market is based on the segments of the manufacturing process, API formulation, application, type of synthesis, molecule, and region. The market segmentation by type of synthesis consists of biotech and synthetic segments. The synthetic segment in 2017 was worth USD 132,690.7 Mn. The manufacturing process based segmentation of the market comprises of contract manufacturing and captive manufacturing. The captive manufacturing segment presently has the significant market share and is expected to remain extremely lucrative throughout the assessment period. The API formulation segments the market into innovative API and generic API. The generic API segment presently held the leading market share in 2017. The segmentation based on molecule has been segmented into small molecule and large molecule. The small molecule segment is expected to maintain its top position till the end of 2023. The application based segmentation of the market has been segmented into oncology, cardiovascular disease, orthopedic disorders, neurological disorders, respiratory, urology, gastrointestinal disorders and others. The oncology segment is anticipated to develop with an incremental CAGR during the forecast period.

Regional Analysis

The market for APIs has been segmented into Europe, Americas, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas region presently controls the significant market portion, and the trend will probably carry on in the foreseeable future. This factor is majorly related to the robust value sustained by the small molecule segment in both Canada and the U.S. Additionally the pharmaceutical industry is among one of the major and most exceptional ventures in the US nations. The pharmaceutical organizations in the USA have developed quickly in comparison with other countries. The European and Asia Pacific region are also anticipated to continue growth in the revenue pockets for the active pharmaceutical ingredients (API) market during the forecast period. Europe accounts for the second largest market for active pharmaceutical ingredients which is followed by the Asia Pacific region. While the APAC region, the market’s course is mostly directed by factors such as the amplified level of expense on equipment and infrastructure, expanding initiatives which are motivating investment in APIs from drug makers to increase the capacity to produce APIs.

Competitive Analysis

The players and key trends have created a positive tone for development. The competitors in the market are also leveraging their competitive benefits to secure their development in the market. The market progress by competitors also encompasses strong risk management strategies which are positively motivating the expansion of the market.

Bayer AG, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi, Boehringer Ingelheim GmbH, Abbott Laboratories, GlaxoSmithKline Plc (GSK), Novartis AG, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/active-pharmaceutical-ingredients-market-1385 

Global EClinical Solutions Market to Record an Exponential CAGR by 2023

 Market Highlights

The Global eClinical Solutions Market is estimated to be valued at USD 9434.57 million by 2023 and is expected to register a CAGR of 12.24% during the forecast period.

The clinical data management system (CDMS) dominated the global eClinical solutions market, by type, and is projected to reach USD 2579 million by 2023 owing to the benefits offered by the product such as centralized end-to-end management of clinical trial activities, real-time status tracking, elimination of reliance on manual processes, and maintenance of multiple databases, which improve the overall efficiency of clinical trials. However, the electronic clinical outcome assessment (eCOA) segment is projected to be the fastest-growing segment during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2294 

Americas dominated the market, accounting for the largest share of the market in 2017, and the regional market is expected to register a CAGR of 12.41% during the review period. The European market was the second-largest in 2017. The market is projected to reach USD 4568.70 million by the end of 2023, with the US being the leading market.   

Segment Analysis

The global eClinical solutions market has been segmented on the basis of type, delivery mode, clinical trial phase, and end user.

On the basis of type, the market has been divided into the clinical data management system (CDMS), randomization and trial supply management (RTSM), electronic clinical outcome assessment (eCOA), clinical trial management system (CTMS), electronic trial master files (eTMF), and trial safety & regulatory. The Clinical Data Management System (CDMS) segment held the majority market share in 2017. However, the Electronic Clinical Outcome Assessment (eCOA) segment is anticipated to be the fastest growing, followed by the Clinical Data Management System (CDMS) segment.

On the basis of Delivery Mode, the market has been divided into web-based, cloud-based, and enterprise-based.

Based on Clinical Trial Phase, the market has been segmented into Phase I, Phase II, Phase III, Phase IV. Phase IV segment holds the largest market share in the global eClinical solutions market.

The end user segment is divided into contract research organizations (CROs), pharma/biotech companies, and others. Contract Research Organizations (CROs) is dominating the market due to the rising clinical trials outsourcing to contract research organizations.

Market Players

Market Research Future (MRFR) recognizes PAREXEL International Corporation, ERT Clinical, CRF Health, Oracle Corporation, BioClinica, Inc., DATATRAK International, Inc., Merge Healthcare Inc, Medidata Solutions, Inc., Omnicomm Systems, Inc. and MaxisIT as the key players in the global eClinical solutions market.

Regional Analysis

Geographically, the global eClinical solutions market has been segmented into North America, Europe, Asia-Pacific, and the rest of the world. As per MRFR analysis, Americas was the largest market for eClinical solutions in 2017 and is expected to remain dominant during the review period. Europe accounted for a significant market share and is projected to be the second-largest market during the forecast period. The growing clinical trials and the need for advanced treatments, along with a growing need for better healthcare infrastructure are the major driving factor for the growth of the eClinical solutions market in Europe.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/eclinical-solution-market-2294